150 related articles for article (PubMed ID: 18483358)
21. Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells.
Lin KT; Yeh SH; Chen DS; Chen PJ; Jou YS
J Biomed Sci; 2005 Oct; 12(5):803-13. PubMed ID: 16132114
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
[TBL] [Abstract][Full Text] [Related]
23. CD9 expression on lymphatic vessels in head and neck mucosa.
Erovic BM; Neuchrist C; Kandutsch S; Woegerbauer M; Pammer J
Mod Pathol; 2003 Oct; 16(10):1028-34. PubMed ID: 14559986
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Mateo G; Montalbán MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutiérrez N; Rosiñol L; Montejano L; Bladé J; Martínez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF; ;
J Clin Oncol; 2008 Jun; 26(16):2737-44. PubMed ID: 18443352
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia.
Roman-Gomez J; Agirre X; Jiménez-Velasco A; Arqueros V; Vilas-Zornoza A; Rodriguez-Otero P; Martin-Subero I; Garate L; Cordeu L; San José-Eneriz E; Martin V; Castillejo JA; Bandrés E; Calasanz MJ; Siebert R; Heiniger A; Torres A; Prosper F
J Clin Oncol; 2009 Mar; 27(8):1316-22. PubMed ID: 19164206
[TBL] [Abstract][Full Text] [Related]
26. Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation.
Suzuki M; Tachibana I; Takeda Y; He P; Minami S; Iwasaki T; Kida H; Goya S; Kijima T; Yoshida M; Kumagai T; Osaki T; Kawase I
J Immunol; 2009 May; 182(10):6485-93. PubMed ID: 19414803
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression.
Maeda G; Chiba T; Kawashiri S; Satoh T; Imai K
Clin Cancer Res; 2007 Sep; 13(17):5041-7. PubMed ID: 17785555
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.
Rendtlew Danielsen JM; Knudsen LM; Dahl IM; Lodahl M; Rasmussen T
Br J Haematol; 2007 Sep; 138(6):756-60. PubMed ID: 17760807
[TBL] [Abstract][Full Text] [Related]
29. CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans.
Kurzeder C; Koppold B; Sauer G; Pabst S; Kreienberg R; Deissler H
Int J Mol Med; 2007 Feb; 19(2):325-33. PubMed ID: 17203208
[TBL] [Abstract][Full Text] [Related]
30. Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells.
Kim B; Rincón Castro LM; Jawed S; Niles LP
Eur J Pharmacol; 2008 Jul; 589(1-3):45-8. PubMed ID: 18550052
[TBL] [Abstract][Full Text] [Related]
31. Expression and function of CD9 in melanoma cells.
Fan J; Zhu GZ; Niles RM
Mol Carcinog; 2010 Jan; 49(1):85-93. PubMed ID: 19777564
[TBL] [Abstract][Full Text] [Related]
32. Differential repetitive DNA methylation in multiple myeloma molecular subgroups.
Bollati V; Fabris S; Pegoraro V; Ronchetti D; Mosca L; Deliliers GL; Motta V; Bertazzi PA; Baccarelli A; Neri A
Carcinogenesis; 2009 Aug; 30(8):1330-5. PubMed ID: 19531770
[TBL] [Abstract][Full Text] [Related]
33. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D; Luetkens T; Hildebrandt Y; Arfsten J; Bartels K; Horn C; Stahl T; Cao Y; Zander AR; Bokemeyer C; Kröger N
Clin Cancer Res; 2009 Feb; 15(4):1343-52. PubMed ID: 19190130
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population.
Gavin DP; Kartan S; Chase K; Jayaraman S; Sharma RP
J Psychiatr Res; 2009 Jun; 43(9):870-6. PubMed ID: 19187942
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Law AY; Lai KP; Lui WC; Wan HT; Wong CK
Exp Cell Res; 2008 Oct; 314(16):2975-84. PubMed ID: 18652825
[TBL] [Abstract][Full Text] [Related]
37. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer.
Hu XT; Zhang FB; Fan YC; Shu XS; Wong AH; Zhou W; Shi QL; Tang HM; Fu L; Guan XY; Rha SY; Tao Q; He C
Oncogene; 2009 Jul; 28(26):2466-75. PubMed ID: 19448674
[TBL] [Abstract][Full Text] [Related]
38. N-glycosylation is required for binding of murine pregnancy-specific glycoproteins 17 and 19 to the receptor CD9.
Ha CT; Waterhouse R; Warren J; Zimmermann W; Dveksler GS
Am J Reprod Immunol; 2008 Mar; 59(3):251-8. PubMed ID: 18275518
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of MIR203 in multiple myeloma.
Wong KY; Liang R; So CC; Jin DY; Costello JF; Chim CS
Br J Haematol; 2011 Sep; 154(5):569-78. PubMed ID: 21707582
[TBL] [Abstract][Full Text] [Related]
40. Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis.
Bock O; Muth M; Theophile K; Winter M; Hussein K; Büsche G; Kröger N; Kreipe H
Br J Haematol; 2009 Sep; 146(5):510-20. PubMed ID: 19604240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
